Recombinant Human CDKN2D Protein，His

CDKN2D, also known as p19INK4d, is a member of the INK4 family of cyclin-dependent kinase inhibitors (CDKIs) that plays a crucial role in regulating the cell cycle. As a tumor suppressor, CDKN2D is involved in the inhibition of CDK4 and CDK6, thereby preventing the phosphorylation of retinoblastoma (Rb) protein and controlling the progression of the cell cycle from the G1 phase to the S phase. Studies have shown that alterations in the CDKN2D gene are linked to various malignancies, particularly in hematological cancers and certain solid tumors, positioning it as a potential biomarker for cancer prognosis and therapy. The investigation of recombinant CDKN2D protein has gained traction in recent years, aiming to elucidate its function, regulatory mechanisms, and its role in cancer biology. By producing CDKN2D in a recombinant form, researchers can analyze its interactions with other cell cycle regulators and assess its potential as a therapeutic target. Such studies contribute to a deeper understanding of tumorigenesis and may lead to the development of novel strategies for cancer treatment that leverage the tumor-suppressive properties of CDKN2D. Additionally, the recombinant protein could serve as a valuable tool for high-throughput screening of small molecules that may activate or mimic its function, thereby offering new avenues for therapeutic intervention in tumors with compromised CDKN2D activity. Ultimately, comprehensive research into CDKN2D and its recombinant protein has the potential to significantly advance our understanding of cancer biology and provide new insights for developing targeted therapies.